WHO Drug Information Vol. 17, No. 4, 2003
(2003; 58 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory Challenges
Cerrar esta carpetaSafety and Efficacy Issues
Ver el documentoMaternal use of SSRIs and neonatal effects
Ver el documentoACE inhibitor, diuretic and NSAID: a dangerous combination
Ver el documentoSerious gastrointestinal effects with celecoxib and rofecoxib
Ver el documentoBisphosphonates and ocular disorders
Ver el documentoFluticasone and adrenal suppression
Ver el documentoAdhesion prevention solutions in gynecological procedures
Ver el documentoTreatment study for West Nile virus
Ver el documentoBlue discoloration and death from FD&C Blue No. 1
Ver el documentoAtazanavir and tenofovir combination cautioned
Ver el documentoRofecoxib, celecoxib and cardiovascular risk
Ver el documentoConvulsions and blood dyscrasias with mirtazapine
Ver el documentoAnti-epileptic drugs, pregnancy and fetal malformations
Abrir esta carpeta y ver su contenidoAspects of Quality Assurance
Abrir esta carpeta y ver su contenidoRegulatory and Safety Action
Abrir esta carpeta y ver su contenidoPersonal Perspectives
Abrir esta carpeta y ver su contenidoCurrent Topics
Abrir esta carpeta y ver su contenidoEssential Medicines
Ver el documentoRecommended International Nonproprietary Names: List 50
Ver el documentoSelected WHO Publications of Related Interest
 

ACE inhibitor, diuretic and NSAID: a dangerous combination

The control of hypertension by ACE inhibitors and diuretics and their beneficial effects in heart failure are antagonized by NSAIDs*. Concurrent use of NSAIDs and diuretics is associated with a twofold increase in the risk of hospitalization for heart failure compared with diuretics alone (1). Moreover, ACE inhibitors, NSAIDs and diuretics, individually or in combination, are involved in over 50% of cases of iatrogenic acute renal failure reported to the Australian Adverse Drug Reactions Advisory Committee (ADRAC).

* Ed. note. Referenced articles not mention use of acetylsalicylic acid as an NSAID.


More specifically, the combined use of ACE inhibitors, diuretics and NSAIDs, termed the "triple whammy", is implicated in a significant number of reports to ADRAC of drug-induced renal failure (2). This effect is also seen with COX-2 inhibitors and angiotensin receptor antagonists ("sartans") (3). In 2002, 28 of the 129 reports to ADRAC of acute renal failure implicated one of these combinations. Most reports to ADRAC of drug-induced renal failure relate to elderly patients, and this applies as well to renal failure associated with the triple therapy (median age 76 years). The fatality rate for ADRAC cases of renal failure with the "triple whammy" is 10%.

The use of ACE inhibitors and angiotensin receptor antagonists is increasing, as is the use of these agents in combination products with a diuretic. Episodes of renal failure appear to be precipitated by mild stress (e.g. diarrhoea, dehydration) in a patient taking the triple combination or by the addition of a third drug (usually an NSAID) to the stable use of the other two. ADRAC suspects that the risk of acute renal failure is underestimated and the syndrome underrecognized.

Extracted from the Australian Adverse Drug Reactions Bulletin, Volume 22, Number 4, August 2003.


References

1. Heerdink, E.R., Leufkens, H.G., Herings, R.M.C. et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Archives of Internal Medicine, 158: 1108 - 1112 (1998).

2. ADRAC, Thomas M. Diuretics, ACE inhibitors and NSAIDs - the triple whammy. Medical Journal of Australia, 172: 184 - 185 (2000).

3. Boyd, I.W., Mathew, T.H., Thomas, M.C. COX-2 inhibitors and renal failure: the triple whammy revisited. Medical Journal of Australia, 173: 274 (2000). (corr. MJA 173: 504, 2000).

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013